; and (2) establish a process, to be used in the case of a pandemic or during times when influenza antiviral supply availability is challenged, to ensure rapid and effective distribution of products to areas of urgent need in close coordination with manufacturers, distributors, and State and local health officials. (j) Plan for ensuring access to appropriate influenza therapeutics, preexposure prophylaxis, and diagnostics (1) In general Not later than 1 year after the date of enactment of this Act, the Secretary of Health and Human Services shall publish a plan for ensuring access to appropriate influenza therapeutics, preexposure prophylaxis influenza antibody products, and influenza diagnostics, including during times when availability is challenged in certain regions or localities, for— (A) high-risk patients, such as nursing home and pediatric patients; (B) high-exposure patients, such as first responders and health care workers; and (C) low-income individuals, individuals covered by Medicaid, uninsured individuals, Tribal communities, and other underserved populations. (2) Communications efforts The plan required by paragraph (1) shall include communications efforts to educate the public about the benefits of early use of influenza diagnostics, therapeutics, and preexposure prophylaxis products. (k) GAO review on transferring COVID–19 technologies (1) In general Not later than six months after the date of enactment of this Act, the Comptroller General of the United States shall conduct a review of the technology and systems utilized by the Centers for Disease Control and Prevention, the Administration for Strategic Preparedness and Response, Operation Warp Speed, the Countermeasure Acceleration Group, H–CORE, and other current and historical departments and agencies involved in the COVID–19 response for surveillance and tracking of COVID–19 cases, treatments, and vaccines, with particular focus on— (A) disease surveillance; (B) vaccine surveillance